iShares Neuroscience and Healthcare ETF

IBRN
ETF Ticker

-2.75%

+15.28%

NYSE Arca Exchange

Equity

Global

Thematic

The iShares Neuroscience and Healthcare ETF, IBRN_US, is listed on the NYSE Arca Exchange and tracks the NYSE FactSet Global Neuro Biopharma and MedTech index. The fund provides exposure to Global, Thematic Equity and has assets under management of $7.8m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Aug 24, 2022. It has a net expense ratio of 47bps. (All data in USD as of Oct 12, 2026 unless stated.)

The underlying NYSE FactSet Global Neuro Biopharma and MedTech Index (USD) offers global, float-adjusted market-cap exposure to companies focused on neurology biopharmaceuticals and neurological devices. The universe spans 44 developed and emerging markets, requiring an eligible equity security to have float-adjusted market cap of at least USD 100 million and three-month ADTV of at least USD 1 million, with buffers of USD 75 million and USD 750,000 for existing constituents. Companies must be classified in FactSet RBICS Neurology Biopharmaceuticals or Neurology Devices, with that sub-industry representing at least 50% of revenues or, for pre-revenue issuers, the primary business based on pipeline. Issuers flagged for psychedelics or cannabis involvement via business descriptions, trade names or supply-chain links are excluded. Constituents are weighted by float-adjusted market cap with a 4% single-stock cap, the index is reconstituted in March and September, and weights are rebalanced quarterly.

ETF Details

Key Facts

Issuer:
iShares
AUM:
$7.8m (as of Aug 31, 2026)
Net Expense Ratio:
47 bps
Inception Date:
Aug 24, 2022
Index:
NYSE FactSet Global Neuro Biopharma and MedTech Index
Dividend Frequency:
Quarterly

Trading

Ticker:
IBRN
Exchange:
NYSE Arca Exchange
ISIN:
US46436E3532
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Global Markets
1 Year Volatility:
26.26%
3 Year Volatility:
25.50%
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
1.16% (verify with issuer)
1 Month Performance:
-16.02%
3 Month Performance:
-19.52%
6 Month Performance:
-6.23%
1 Year Performance:
15.28%
3 Year Performance:
54.17%
5 Year Performance:
N/A
Investment Proposition

iShares Neuroscience and Healthcare ETF (IBRN) presents global exposure to companies advancing brain-related therapeutics, diagnostics, devices, and enabling technologies across biopharma, medtech, and life-science tools. The strategy targets firms positioned to benefit from innovation addressing neurological disorders and cognitive health, spanning discovery to commercialization. Performance is driven by clinical trial milestones, regulatory outcomes, intellectual property durability, and adoption by providers and payers, with style tilts that can range from growth to biotech-small/mid depending on the opportunity set. The theme can be resilient when healthcare demand is steady and innovation pipelines deliver, yet it is vulnerable to binary event risk, reimbursement shifts, and capital-market conditions for research-intensive companies. Potential portfolio roles include a thematic satellite for long-horizon growth, a targeted healthcare tilt to complement broad sector exposure, or a research-led sandbox sleeve within an alternatives bucket. Suitable investors include allocators seeking exposure to the translation of neuroscience research into commercial platforms and advisors constructing diversified healthcare stacks. A key fund-specific risk is clinical and regulatory concentration, where setback clustering can elevate volatility and tracking variability.

ETF Analytics

Fund Discovery

4 Suggestions